Insider Trading March 26, 2026

Howard Hughes COO Disposes $104,491 in Shares; Company Posts Mixed Q4 2025 Results

Andrew D. Davis sold 1,636 shares while Howard Hughes delivered a revenue beat alongside a sizeable EPS shortfall

By Priya Menon HHH
Howard Hughes COO Disposes $104,491 in Shares; Company Posts Mixed Q4 2025 Results
HHH

Howard Hughes Holdings Inc.'s Chief Operating Officer, Andrew D. Davis, reported a sale of 1,636 shares on March 25, 2026, for $104,491, leaving him with 31,530 shares. Separately, the company’s fourth-quarter 2025 results showed a revenue beat of $624.4 million versus $596.8 million expected, but an earnings per share of $0.10 fell well below the $0.39 forecast.

Key Points

  • Howard Hughes COO Andrew D. Davis sold 1,636 shares on March 25, 2026, at $63.87 per share, totaling $104,491.
  • After the sale, Davis directly owns 31,530 shares of the company.
  • Fourth-quarter 2025 results were mixed: EPS of $0.10 missed the $0.39 consensus (negative surprise of 74.36%), while revenue of $624.4 million beat the $596.8 million estimate.

Andrew D. Davis, the Chief Operating Officer of Howard Hughes Holdings Inc (NYSE: HHH), disclosed a sale of 1,636 shares of the company’s common stock on March 25, 2026, in a Form 4 filing with the Securities and Exchange Commission. The transaction took place at $63.87 per share, producing total proceeds of $104,491. After completing the sale, Davis directly holds 31,530 shares of the firm.

The insider transaction coincides with the company’s recently released fourth-quarter 2025 financial results, which present a mixed picture. Howard Hughes reported earnings per share (EPS) of $0.10 for the quarter, below the consensus estimate of $0.39, representing a negative surprise of 74.36%. At the same time, the company recorded revenue of $624.4 million, exceeding the anticipated $596.8 million.

These outcomes highlight a divergence between top-line performance and bottom-line profitability for the quarter. While revenues outpaced expectations, the EPS shortfall indicates that higher sales did not translate into the level of earnings the market had projected. The company’s reported results and the insider sale were disclosed separately in regulatory filings and earnings announcements.

No analyst upgrades or downgrades were mentioned in relation to the quarter’s results. The absence of reported changes from analysts leaves the market interpretation to investors and other observers, who may continue to watch forthcoming reports and disclosures for additional clarity on operational efficiency and profitability.


Key details

  • Insider transaction: Andrew D. Davis sold 1,636 shares on March 25, 2026, at $63.87 per share, totaling $104,491.
  • Post-transaction holdings: Davis directly owns 31,530 shares of Howard Hughes Holdings Inc.
  • Quarterly results: Q4 2025 EPS $0.10 versus $0.39 expected (negative surprise 74.36%); revenue $624.4 million versus $596.8 million expected.

Investor implications and outlook

The combination of an insider sale and mixed quarterly metrics underscores the complexity of the company’s near-term financial picture. The revenue beat signals robust sales activity for the quarter, but the significant EPS shortfall points to factors limiting profitability during the same period. With no analyst rating changes reported alongside the results, market participants will likely focus on subsequent disclosures and operational updates for clearer signals on future performance.

Risks

  • Profitability risk - Despite a revenue beat, the substantial EPS shortfall indicates challenges converting sales into expected earnings, which may affect investor confidence in near-term profitability.
  • Analyst coverage uncertainty - No analyst upgrades or downgrades were reported alongside the results, leaving a gap in external guidance and potentially increasing volatility as investors await further clarity.
  • Insider activity interpretation - The reported sale by a senior executive could be viewed variably by market participants; without additional context, it introduces uncertainty around insider sentiment.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026